S-rivastigmine-duloxetine | 1104546-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: S-rivastigmine-duloxetine
• 英文别名: [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-methyl-N-[(3S)-3-naphthalen-1-yloxy-3-thiophen-2-ylpropyl]carbamate
• CAS: 1104546-22-6
• 化学式: C₂₉H₃₂N₂O₃S
• 分子量: 488.651
• InChiKey: CKTLFWLBOQRPST-IDISGSTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Compounds that inhibit cholinesterase
  申请人：Rupniak Nadia M. J.

  公开号：US20080261950A1

  公开（公告）日：2008-10-23

  Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.
• Methods for promoting wakefulness
  申请人：Rupniak Nadia M.J.

  公开号：US20090048229A1

  公开（公告）日：2009-02-19

  The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.
• Stigmine Conjugates for Substance Use Disorders
  申请人：Rupniak Nadia

  公开号：US20110251175A1

  公开（公告）日：2011-10-13

  The invention relates to methods for the treatment or prevention of substance use disorders.
• US8101782B2
  申请人：——

  公开号：US8101782B2

  公开（公告）日：2012-01-24